479 related articles for article (PubMed ID: 33804869)
41. Innate immune cells in the tumor microenvironment.
Li MO; Wolf N; Raulet DH; Akkari L; Pittet MJ; Rodriguez PC; Kaplan RN; Munitz A; Zhang Z; Cheng S; Bhardwaj N
Cancer Cell; 2021 Jun; 39(6):725-729. PubMed ID: 34129817
[TBL] [Abstract][Full Text] [Related]
42. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.
Moynihan KD; Opel CF; Szeto GL; Tzeng A; Zhu EF; Engreitz JM; Williams RT; Rakhra K; Zhang MH; Rothschilds AM; Kumari S; Kelly RL; Kwan BH; Abraham W; Hu K; Mehta NK; Kauke MJ; Suh H; Cochran JR; Lauffenburger DA; Wittrup KD; Irvine DJ
Nat Med; 2016 Dec; 22(12):1402-1410. PubMed ID: 27775706
[TBL] [Abstract][Full Text] [Related]
43. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors.
Ciccarese C; Alfieri S; Santoni M; Santini D; Brunelli M; Bergamini C; Licitra L; Montironi R; Tortora G; Massari F
Expert Opin Drug Metab Toxicol; 2016; 12(1):57-75. PubMed ID: 26565919
[TBL] [Abstract][Full Text] [Related]
44. Mechanisms of Immune Tolerance in Leukemia and Lymphoma.
Curran EK; Godfrey J; Kline J
Trends Immunol; 2017 Jul; 38(7):513-525. PubMed ID: 28511816
[TBL] [Abstract][Full Text] [Related]
45. Influence of Galectin-9 Treatment on the Phenotype and Function of NK-92MI Cells in the Presence of Different Serum Supplements.
Meggyes M; Nagy DU; Balassa T; Godony K; Peterfalvi A; Szereday L; Polgar B
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439744
[TBL] [Abstract][Full Text] [Related]
46. Programming the immune checkpoint to treat hematologic malignancies.
Vick E; Mahadevan D
Expert Opin Investig Drugs; 2016 Jul; 25(7):755-70. PubMed ID: 27070269
[TBL] [Abstract][Full Text] [Related]
47. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.
Voeller J; Erbe AK; Slowinski J; Rasmussen K; Carlson PM; Hoefges A; VandenHeuvel S; Stuckwisch A; Wang X; Gillies SD; Patel RB; Farrel A; Rokita JL; Maris J; Hank JA; Morris ZS; Rakhmilevich AL; Sondel PM
J Immunother Cancer; 2019 Dec; 7(1):344. PubMed ID: 31810498
[TBL] [Abstract][Full Text] [Related]
48. Three steps to breaking immune tolerance to lymphoma: a microparticle approach.
Makkouk A; Joshi VB; Lemke CD; Wongrakpanich A; Olivier AK; Blackwell SE; Salem AK; Weiner GJ
Cancer Immunol Res; 2015 Apr; 3(4):389-98. PubMed ID: 25627654
[TBL] [Abstract][Full Text] [Related]
49. Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
Brempelis KJ; Cowan CM; Kreuser SA; Labadie KP; Prieskorn BM; Lieberman NAP; Ene CI; Moyes KW; Chinn H; DeGolier KR; Matsumoto LR; Daniel SK; Yokoyama JK; Davis AD; Hoglund VJ; Smythe KS; Balcaitis SD; Jensen MC; Ellenbogen RG; Campbell JS; Pierce RH; Holland EC; Pillarisetty VG; Crane CA
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33115946
[TBL] [Abstract][Full Text] [Related]
50. Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion.
Liu X; Liu L; Ren Z; Yang K; Xu H; Luan Y; Fu K; Guo J; Peng H; Zhu M; Fu YX
Cell Rep; 2018 Aug; 24(8):2101-2111. PubMed ID: 30134171
[TBL] [Abstract][Full Text] [Related]
51. The tumor microenvironment in follicular lymphoma.
Yang ZZ; Ansell SM
Clin Adv Hematol Oncol; 2012 Dec; 10(12):810-8. PubMed ID: 23271353
[TBL] [Abstract][Full Text] [Related]
52. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.
Barnestein R; Galland L; Kalfeist L; Ghiringhelli F; Ladoire S; Limagne E
Oncoimmunology; 2022; 11(1):2120676. PubMed ID: 36117524
[TBL] [Abstract][Full Text] [Related]
53. Innate immune mediators in cancer: between defense and resistance.
Berraondo P; Minute L; Ajona D; Corrales L; Melero I; Pio R
Immunol Rev; 2016 Nov; 274(1):290-306. PubMed ID: 27782320
[TBL] [Abstract][Full Text] [Related]
54. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.
Stahl M; Gedrich R; Peck R; LaVallee T; Eder JP
Immunotherapy; 2016 Jun; 8(7):767-74. PubMed ID: 27349976
[TBL] [Abstract][Full Text] [Related]
55. Immune checkpoint blockade in lymphoid malignancies.
Thanarajasingam G; Thanarajasingam U; Ansell SM
FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
[TBL] [Abstract][Full Text] [Related]
56. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
57. Heat Shock Proteins in Lymphoma Immunotherapy.
Albakova Z; Mangasarova Y; Sapozhnikov A
Front Immunol; 2021; 12():660085. PubMed ID: 33815422
[TBL] [Abstract][Full Text] [Related]
58. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
59. Genetic alterations shape innate immune cells to foster immunosuppression and cancer immunotherapy resistance.
Kwantwi LB
Clin Exp Med; 2023 Dec; 23(8):4289-4296. PubMed ID: 37910258
[TBL] [Abstract][Full Text] [Related]
60. Immune and Cell Therapy in Non-Hodgkin Lymphoma.
Merryman RW; Houot R; Armand P; Jacobson C
Cancer J; 2020; 26(3):269-277. PubMed ID: 32496460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
